BLI-1401 is a new indication of BLI-1301, which is extracted from Grifola frondosa, a special fungus enhancing immunity and reducing side effects of chemotherapy. It is developed as a cancer combination therapy for solid tumors.
Drug Type
New drug category: Botanical new drug
Formulation: Oral
Foresight and Global Development
There were approximately 14 million new cases and 8.2 million cancer-related deaths in 2012, and the number of new cases is expected to rise by about 70% in the next two decades. However, current cancer therapies such as chemotherapy, monoclonal antibodies, or hormone therapies are often associated with severe side effects, drug resistance, and limited therapeutic effects. Therefore, combination therapies that can reduce the side effects of current cancer therapies present great opportunity for cancer patients.
Result
BLI-1401 is a botanical investigational new drug which has shown notable potential as an anticancer therapy by enhancing human immune system. In two clinical trials investigating myelodysplastic syndromes patients and breast cancer patients, respectively, BLI-1401 enhanced the function of various types of immune cells such as lymphocyte, monocyte and neutrophil. These enhancements might prolong the survival of cancer patients, even curing the cancer.
A recent study indicated that BLI-1401 plus cisplatin, a chemotherapy drug, can not only enhance antitumor and anti-metastatic activity than cisplatin-treatment alone, but also reduce cisplatin-induced severe side effects.
Product Advantage
BLI-1401 is a safe active ingredient extracted from edible mushrooms. Several human and animal studies have shown that BLI-1401 enhanced immune system and repaired hematopoietic stem cells.
Animal studies showed that in combination with conventional cancer therapy, BLI-1401 not only enhanced cytotoxicity to cancer cells but also effectively reduced neurotoxicity of the treatments and repaired hematopoietic stem cells.
BLI-1401 has been tested by professional teams from Japan and US Cancer Centers in Phase I and II Clinical Trials.
BLI-1401 is a natural substance from fugus with long history of use, higher safety, and fewer side effects compared to NCEs. Oral administration enhances patient compliance.
BLI-1401 is covered by patents in 7 countries as the US, United Kingdom, Japan, Germany, France, Italy, and China.
